Atorvastatin
A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.
น้ำหนักโมเลกุล
558.6400 g/mol
LogP
5.00
TPSA
112.00 Ų
Lipinski RO5
ผ่าน
ด้านการรักษา
หมวดหมู่ยา
กลไกการออกฤทธิ์
Competitive inhibitor of HMG-CoA reductase.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitive inhibitor of HMG-CoA reductase.
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
InChI
InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
Molecular Formula
C33H35FN2O5
HBD / HBA
4 / 6
พันธะที่หมุนได้
12
อะตอมหนัก
41
Cyclosporine dramatically increases atorvastatin plasma levels through combined inhibition of CYP3A4, OATP1B1, and P-gp, substantially raising the risk of myopathy and rhabdomyolysis.
Doxycycline may slightly raise atorvastatin plasma levels through weak inhibition of CYP3A4 and P-glycoprotein, though clinically significant myopathy from this combination is rarely reported.
Diltiazem inhibits CYP3A4-mediated atorvastatin metabolism, increasing atorvastatin plasma concentrations and the risk of myopathy and rhabdomyolysis.
Amlodipine weakly inhibits CYP3A4-mediated atorvastatin metabolism, leading to a modest increase in atorvastatin exposure; the combination is generally used safely in clinical practice.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
A statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, substantially lowering LDL cholesterol levels and reducing the risk of heart attack and stroke. It is one of the most widely prescribed medications worldwide.
Competitive inhibitor of HMG-CoA reductase.
Key pharmacokinetic parameters for Atorvastatin: Half-life: 14 hours.
Yes, Atorvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1487. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 60823. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="atorvastatin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/atorvastatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/atorvastatin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/atorvastatin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="atorvastatin"></drugfyi-drug>